Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
Synaptic density imaging in behavioral variant frontotemporal dementia: A comparison of 1 8F-SynVesT-1 and 1 8F-FDG PET.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fesharaki-Zadeh Arman, Cayir Salih, Ibrahim Waleed, Yang Yanghong, Gallezot Jean-Dominique, Naganawa Mika, Wu Yanjun, Toyonaga Takuya, Sadabad Faranak Ebrahimian, O'Dell Ryan, Pittman Brian, Nabulsi Nabeel, Strittmatter Stephen, Carson Richard E, Huang Yiyun, van Dyck Christopher H, Mecca Adam P, Matuskey David
Аннотация
INTRODUCTION: Synapse loss, a key feature of behavioral variant frontotemporal dementia (bvFTD), can now be visualized in vivo using positron emission tomography (PET) that targets synaptic vesicle glycoprotein 2A (SV2A). Comparing this new imaging method with the clinical standard of glucose metabolism using 1 8F-fluorodeocyglucose (1 8F-FDG) PET might improve diagnostic accuracy and disease monitoring in bvFTD.
METHODS: We measured synaptic vesicle glycoprotein 2A (SV2A) binding using 1 8F-SynVesT-1 PET and glucose metabolism with 1 8F-FDG PET in 10 patients with bvFTD and 10 age-matched healthy controls.
RESULTS: SV2A binding was significantly lower in the frontal and temporal cortices, anterior cingulate, and insula in bvFTD patients, with more widespread and pronounced differences than those observed with 1 8F-FDG PET. SV2A binding in the frontal cortex and insula significantly correlated with the Frontal Assessment Battery scores.
DISCUSSION: Our findings suggest that, in bvFTD, the degree of lower synaptic density, as measured by SV2A PET, is larger than the degree of hypometabolism as measured by 1 8F-FDG PET. SV2A imaging demonstrates considerable promise as a new in vivo biomarker for bvFTD.
METHODS: We measured synaptic vesicle glycoprotein 2A (SV2A) binding using 1 8F-SynVesT-1 PET and glucose metabolism with 1 8F-FDG PET in 10 patients with bvFTD and 10 age-matched healthy controls.
RESULTS: SV2A binding was significantly lower in the frontal and temporal cortices, anterior cingulate, and insula in bvFTD patients, with more widespread and pronounced differences than those observed with 1 8F-FDG PET. SV2A binding in the frontal cortex and insula significantly correlated with the Frontal Assessment Battery scores.
DISCUSSION: Our findings suggest that, in bvFTD, the degree of lower synaptic density, as measured by SV2A PET, is larger than the degree of hypometabolism as measured by 1 8F-FDG PET. SV2A imaging demonstrates considerable promise as a new in vivo biomarker for bvFTD.